GlassScriptPhysician profile
Lindsey Cilia
NPI 1013329903
$49,833.34
in general payments reported to CMS, 2019-2025
29 companies · $38K in 2025
The $38K reported for 2025 was more than what 96% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $128 · 2021: $1,219 · 2022: $1,172 · 2023: $3,560 · 2024: $5,443 · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,875 · Travel and Lodging: $3,935 · Honoraria: $500 · Education: $89.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,737.50 |
| Food and Beverage | $11,177.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,875.00 |
| Travel and Lodging | $3,935.25 |
| Honoraria | $500.00 |
| Education | $89.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23,482.72 | 2021-2025 | Optis, Pressurewire, Diamondback Coronary |
| Boston Scientific Corporation | $13,448.03 | 2022-2025 | General - Vascular Access, General - Therapies, Avvigo Guidance System |
| Abiomed | $2,792.68 | 2022-2025 | Impella |
| Asahi Intecc USA, INC. | $2,442.04 | 2023-2025 | Asahi Coronary Wires, Asahi Ptca Guide Wire, Peripheral Vascular |
| Heartflow, INC. | $1,400.00 | 2025 | |
| Medtronic, INC. | $1,222.97 | 2021-2025 | Onyx Frontier, Symplicity G3 |
| Cardiovascular Systems INC. | $1,080.17 | 2021-2023 | Diamondback Coronary |
| Teleflex LLC | $982.53 | 2023-2025 | Guideliner, Turnpike, Supercross |
| Biotronik INC. | $792.70 | 2020-2023 | Orsiro Mission |
| Shockwave Medical, INC | $529.26 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Terumo Medical Corporation | $441.27 | 2023-2025 | Metacross Otw, Glidewire, Heartrail |
| Chiesi USA, INC. | $393.64 | 2021-2025 | Kengreal |
| Penumbra, INC. | $133.54 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $81.86 | 2024-2025 | Camzyos |
| Seigla Medical, INC. | $81.84 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.76 | 2020-2025 | Lifevest |
| Astellas Pharma US INC | $79.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $79.83 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $46.16 | 2024-2025 | Farxiga |
| Novo Nordisk INC | $40.82 | 2025 | Wegovy |
| Amgen INC. | $36.13 | 2025 | Repatha |
| Philips North America LLC | $27.70 | 2020 | |
| Scpharmaceuticals INC. | $26.09 | 2025 | |
| Pfizer INC. | $25.97 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $25.41 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $20.19 | 2024 | Opsumit |
| Merck Sharp & Dohme LLC | $19.11 | 2023 | Verquvo |
| Esperion Therapeutics, INC. | $14.11 | 2024 | Nexletol |
| Reflow Medical INC | $4.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Cilia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.